TISIDB

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Membrane Single-pass type I membrane protein
Domain	PF00431 CUB domain PF12947 EGF domain PF07645 Calcium-binding EGF domain PF00053 Laminin EGF domain PF01437 Plexin repeat
Function	Acts as a negative regulator of hedgehog signaling.

> Gene Ontology [ TOP ]
Biological Process	GO:0001501 skeletal system development GO:0001558 regulation of cell growth GO:0001667 ameboidal-type cell migration GO:0001702 gastrulation with mouth forming second GO:0002011 morphogenesis of an epithelial sheet GO:0003002 regionalization GO:0003007 heart morphogenesis GO:0003143 embryonic heart tube morphogenesis GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007368 determination of left/right symmetry GO:0007369 gastrulation GO:0007389 pattern specification process GO:0007409 axonogenesis GO:0007411 axon guidance GO:0007413 axonal fasciculation GO:0007507 heart development GO:0008037 cell recognition GO:0008038 neuron recognition GO:0008361 regulation of cell size GO:0009799 specification of symmetry GO:0009855 determination of bilateral symmetry GO:0010720 positive regulation of cell development GO:0010769 regulation of cell morphogenesis involved in differentiation GO:0010770 positive regulation of cell morphogenesis involved in differentiation GO:0010975 regulation of neuron projection development GO:0010976 positive regulation of neuron projection development GO:0016049 cell growth GO:0022604 regulation of cell morphogenesis GO:0030307 positive regulation of cell growth GO:0030326 embryonic limb morphogenesis GO:0030509 BMP signaling pathway GO:0030516 regulation of axon extension GO:0031346 positive regulation of cell projection organization GO:0032103 positive regulation of response to external stimulus GO:0032535 regulation of cellular component size GO:0035050 embryonic heart tube development GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0035239 tube morphogenesis GO:0040017 positive regulation of locomotion GO:0042074 cell migration involved in gastrulation GO:0045666 positive regulation of neuron differentiation GO:0045773 positive regulation of axon extension GO:0045927 positive regulation of growth GO:0048562 embryonic organ morphogenesis GO:0048565 digestive tract development GO:0048568 embryonic organ development GO:0048588 developmental cell growth GO:0048638 regulation of developmental growth GO:0048639 positive regulation of developmental growth GO:0048667 cell morphogenesis involved in neuron differentiation GO:0048675 axon extension GO:0048704 embryonic skeletal system morphogenesis GO:0048705 skeletal system morphogenesis GO:0048706 embryonic skeletal system development GO:0048736 appendage development GO:0048841 regulation of axon extension involved in axon guidance GO:0048842 positive regulation of axon extension involved in axon guidance GO:0048846 axon extension involved in axon guidance GO:0050769 positive regulation of neurogenesis GO:0050770 regulation of axonogenesis GO:0050772 positive regulation of axonogenesis GO:0050920 regulation of chemotaxis GO:0050921 positive regulation of chemotaxis GO:0051272 positive regulation of cellular component movement GO:0051962 positive regulation of nervous system development GO:0055113 epiboly involved in gastrulation with mouth forming second GO:0055123 digestive system development GO:0060173 limb development GO:0060348 bone development GO:0060349 bone morphogenesis GO:0060560 developmental growth involved in morphogenesis GO:0060562 epithelial tube morphogenesis GO:0060971 embryonic heart tube left/right pattern formation GO:0060972 left/right pattern formation GO:0060976 coronary vasculature development GO:0061371 determination of heart left/right asymmetry GO:0061387 regulation of extent of cell growth GO:0061564 axon development GO:0071772 response to BMP GO:0071773 cellular response to BMP stimulus GO:0071907 determination of digestive tract left/right asymmetry GO:0090066 regulation of anatomical structure size GO:0090504 epiboly GO:0097094 craniofacial suture morphogenesis GO:0097155 fasciculation of sensory neuron axon GO:0097485 neuron projection guidance GO:1902284 neuron projection extension involved in neuron projection guidance GO:1902667 regulation of axon guidance GO:1902669 positive regulation of axon guidance GO:1904888 cranial skeletal system development GO:1990138 neuron projection extension
Molecular Function	-
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MEGF8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MEGF8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	logFC: -3.14; FDR: 0.00545	Resistant to T cell-mediated killing
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MEGF8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.164	0.59
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.557	0.734
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.123	0.92
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.516	0.181
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.838	0.752
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.109	0.974
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.017	0.961
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.156	0.92
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.199	0.909
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.123	0.929
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.605	0.751
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.096	0.21

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MEGF8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	0	14.3	0.196
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	5.5	5.6	0.384
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	6.8	4.3	0.673
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	0	14.3	0.238
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	23.1	0	23.1	0.223
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	18.8	-18.8	0.28
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	22.2	-22.2	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	3.7	6.8	0.393
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	18.2	7.7	10.5	0.63
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MEGF8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MEGF8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MEGF8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MEGF8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MEGF8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MEGF8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MEGF8
Name	multiple EGF-like-domains 8
Aliases	FLJ22365; HBV pre s2 binding protein 1; EGFL4; C19orf49; EGF-like-domain, multiple 4; chromosome 19 open rea ......
Chromosomal Location	19q13.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MEGF8 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MEGF8